Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

February 13, 2018 — Abbott announced the first patient has been enrolled in a...

Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018

January 22, 2018 — Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of...

News | Antiplatelet and Anticoagulation Therapies | January 19, 2018

January 19, 2018 — The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is...

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017

December 12, 2017 — Mayo Clinic researchers have shown a link between which type of...

News | Antiplatelet and Anticoagulation Therapies | November 16, 2017

November 16, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017

November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017

November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at...

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017

September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with...

EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017

September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with...

Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017

August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. announced results from an analysis of real-world data...

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017

August 18, 2017 — Medtronic plc announced a global randomized...

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies | August 16, 2017

August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI)...

Overlay Init